Fed. Circ. Won't Rethink Alimta Double Patenting Decision
The appeals court denied a petition for an en banc rehearing filed by Teva Pharmaceutical Industries Ltd. and other generics makers, leaving in place the court's August ruling that Lilly's patent on pemetrexed — the active ingredient in Alimta — is valid until 2017.
The rejection also means the...
To view the full article, register now.